Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients

NCT06367010 · clinicaltrials.gov ↗

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Neoplasms

Interventions

COMBINATION_PRODUCT: Iodine-125 brachytherapy combine with Anlotinib

Sponsor

Jiangxi Provincial Cancer Hospital